Immunotherapy Significantly Improved Survival in Recurrent/Metastatic Cervical Cancer
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
News
Latest News
dd-MVAC Regimen ‘Should Be Gold Standard’ for Muscle-Invasive Bladder Cancer
Dose-dense methotrexate plus vinblastine, doxorubicin, and cisplatin improved time to progression.
Brigatinib Continues to Best Crizotinib in ALK+ Non-Small Cell Lung Cancer
There was an improvement in progression-free survival despite crossover.
Napabucasin Provides No Added Benefit in Metastatic Pancreatic Cancer
The phase 3 CanStem111P study was terminated early due to futility.
Presence of ctDNA Predicts Worse Outcomes in Early Breast Cancer
The presence of ctDNA, both at baseline and after treatment, was associated with worse survival outcomes.
Real-World Data Suggest Vaccination Reduces Risk of COVID-19 in Patients With Cancer
Most vaccinated patients reported having mild side effects or none at all.
Earlier Elimination of Cervical Cancer Projected in Low-Poverty U.S. Counties
Over the next 50 years, 21,604 cumulative excess cervical cancer cases are estimated in high-poverty counties.
Exkivity Approved for EGFR Exon 20 Insertion+ NSCLC
Exkivity (mobocertinib) is approved to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Baricitinib Does Not Cut COVID-19 Progression in Hospitalized Adults
Baricitinib was associated with reduced mortality.
Cancer Diagnoses Down During the Pandemic
The mean monthly number of new diagnoses of all cancer types combined fell 29.8% during the first pandemic period.
Federal Data Understated COVID-19 Cases, Deaths in Nursing Homes
Estimated cases and deaths omitted represented 11.6% and 14.0% of cases and deaths in nursing home residents in 2020.
Long-Term COVID-19 Symptoms Linked to Treatment, Survival of Cancer Patients
Long-term symptoms included shortness of breath, chronic fatigue, and neurocognitive dysfunction.
Cancer Cases in Europe Projected to Increase About 20% by 2040
The researchers also projected an increase in cancer deaths.
Registry Data Suggest TaTME Is Safe and Effective for Rectal Cancer
The 2-year actuarial rate of local recurrence was 4.8%.
Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib
At 12 weeks, most patients had a reduction in spleen volume.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ESMO 2021
Loading... 
Loading...